This investigation was designed to compare in vitro dissolution profiles fr
om sodium iodide capsules with radioiodide thyroid uptake in hyperthyroid c
ats using sodium iodide capsules prepared with a formulation exhibiting a c
omplete release of radioiodide (I-123) in vitro and a formulation with an i
ncomplete release of radioiodide. In vitro dissolution profiles for I-123 s
odium iodide capsules with two different formulations were determined using
the USP XXIII dissolution test. The two formulations studied in vitro were
sodium phosphate dibasic powder with 1% magnesium stearate and calcium pho
sphate dibasic powder with 3% magnesium stearate. By 20 min after initiatio
n of the dissolution test, over 95% of the I-123 was released from capsules
of sodium phosphate dibasic powder. The capsules of calcium phosphate diba
sic powder reached 7.5% at 65 min, with no further release occurring therea
fter. There was a statistically significant difference in the dissolution p
rofiles of the two formulations. The thyroid uptake of I-123 from capsules
exhibiting complete release and incomplete release of radioiodide was deter
mined in hyper thyroid cats. At 4 hr, the mean percentage thyroid uptake va
lue for sodium phosphate dibasic powder with 1% magnesium stearate (complet
e release formulation) was 12.0% compared to 9.4% for calcium phosphate dib
asic powder with 3% magnesium stearate (incomplete release formulation); at
24 hr; the values were 34.4% compared to 23.7%. The data suggest that the
incomplete dissolution profile observed in vitro may correlate with a reduc
tion ia the bioavailability of the radioiodide in vivo. However, using the
Wilcoxon signed rank test, statistically significant differences did not oc
cur between the complete release formulation and incomplete release formula
tion at either 4 hr or 24 hr (p >.05). The results of the in vivo study wit
h five hyperthyroid cats were not conclusive due to the variability in resp
onse between individual cats.